Skip to main content
Premium Trial:

Request an Annual Quote

Duke Licenses NPM1 from Trovagene for AML Research, Testing

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).

The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.

Trovagene holds the exclusive worldwide license to the patent around NPM1. Duke is the latest licensee of the technology. Last week, Trovagene said that Genoptix licensed rights to use NPM1, and others that have sublicensed the protein include Quest Diagnostics, Laboratory Corporation of America, and Münchner Leukamielabor in Germany.

Trovagene also has co-licensing deals with Asuragen and Ipsogen, part of Qiagen, to manufacture and sell NPM1 mutation kits.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.